New York: Drugmaker Novartis On Wednesday Acknowledged That There Were Discrepancies With Data It Had Submitted To Regulators For Approval Of Its More Than $2 Million Gene Therapy Zolgensma, But Delayed Notifying Authorities Until It Completed Its Internal Investigation.Novartis Faces Possible Civil Or Criminal Penalties From The U.S. Food And Drug
